View Older Stories View More Recent Stories

Jun 5, 2020 06:51AM Merck (MRK) Announces FDA Approves its RECARBRIO for Treatment of Adults with HABP/VABP
Jun 5, 2020 06:50AM FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Jun 1, 2020 06:47AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA Receives Positive Opinion from EU CHMP for First-Line Maintenance Treatment of Patients with gBRCAm
Jun 1, 2020 06:45AM LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for First-Line Maintenance Treatment of Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer
May 28, 2020 06:37PM KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma
May 28, 2020 05:03PM Merck (MRK) Announces KEYTRUDA Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
May 28, 2020 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
May 27, 2020 09:15AM MilliporeSigma and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19
May 26, 2020 12:37PM Merck Announces Third-Quarter 2020 Dividend
May 26, 2020 06:53AM Merck (MRK) Reports Acquisition of Themis
May 26, 2020 06:51AM Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
May 26, 2020 06:49AM IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
May 26, 2020 06:47AM Merck to Acquire Themis
May 26, 2020 06:45AM Merck (MRK) will today announce three significant scientific initiatives to combat COVID-19
May 26, 2020 06:45AM Merck to Announce Multiple Scientific Efforts to Combat COVID-19
May 20, 2020 06:57AM Merck (MRK), AstraZeneca (AZN) Report LYNPARZA (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
May 20, 2020 06:55AM LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
May 19, 2020 07:00AM  Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
May 18, 2020 04:30PM Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
May 18, 2020 04:30PM CORRECTING and REPLACING Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
May 14, 2020 06:45AM Merck to Present at the UBS Virtual Global Healthcare Conference
May 13, 2020 05:04PM Merck (MRK) New Combination Data for KEYTRUDA Demonstrated Clinical Benefit in Stage III NSCLC and Reinforce Long-Term Survival in Metastatic NSCLC
May 13, 2020 05:04PM Merck (MRK) KEYTRUDA Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Negative Breast Ca
May 13, 2020 05:03PM Merck's (MRK) KEYTRUDA Superior to Brentuximab Vedotin, a Standard of Care, in Patients With cHL in Head-to-Head Phase 3 Trial
May 13, 2020 05:02PM Merck (MRK) Novel HIF-2α Inhibitor Showed ORR of Nearly 30% in Patients with VHL Disease-Associated Clear Cell Renal Cell Carcinoma
May 13, 2020 05:00PM Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
May 13, 2020 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
May 13, 2020 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Chemotherapy in Certain Patients with Metastatic Triple-Ne
May 13, 2020 05:00PM New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
May 13, 2020 05:54AM Merck (MRK) Animal Health Reports Acquires U.S. Rights to SENTINEL Brand of Combination Parasiticides for Companion Animals
May 13, 2020 02:00AM Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals
May 13, 2020 01:38AM Virbac to divest U.S. Rights to SENTINEL® brands to MSD Animal Health
May 11, 2020 09:00AM MilliporeSigma Granted U.S. Patents for Foundational CRISPR-Cas9 Technology
May 8, 2020 05:25PM LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
May 8, 2020 06:45AM Merck Announces Virtual 2020 Annual Shareholders Meeting
May 7, 2020 06:55AM Merck to Present at the BofA Securities 2020 Health Care Conference
May 7, 2020 06:45AM Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program
May 6, 2020 06:47AM Merck (MRK) Announces Results of Phase 3 Trial Evaluating RECARBRIO Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Available
May 6, 2020 06:45AM Results of Phase 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™ (Imipenem, Cilastatin, and Relebactam) Versus Piperacillin and Tazobactam in Adult Patients with HABP/VABP Now Ava
May 5, 2020 06:45AM Merck Commits Additional $10 Million to COVID-19 Relief Efforts to Help Disparately Impacted Patients and Communities
Apr 28, 2020 05:08PM Merck (MRK) Announces FDA Approves KEYTRUDA for Use at Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Apr 28, 2020 04:35PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications
Apr 28, 2020 06:45AM Merck Announces First-Quarter 2020 Financial Results
Apr 27, 2020 06:57AM Merck (MRK) Announces First Clinical Outcomes Evaluating Six-Week Dosing Schedule for KEYTRUDA Presented at AACR
Apr 27, 2020 06:55AM First Clinical Outcomes Evaluating Six-Week Dosing Schedule for Merck’s KEYTRUDA® (pembrolizumab) Presented at AACR Virtual Annual Meeting I
Apr 27, 2020 06:46AM Merck (MRK), Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Apr 27, 2020 06:45AM Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
Apr 24, 2020 06:56AM Merck (MRK) Announces LYNPARZA Demonstrated OS Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 24, 2020 06:55AM LYNPARZA® (Olaparib) Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Apr 24, 2020 06:55AM LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
View More Recent Stories View Older Stories